Plague Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Plague Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major plague markets reached a value of US$ 14.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 26.0 Billion by 2034, exhibiting a growth rate (CAGR) of 5.54% during 2024-2034.

The plague market has been comprehensively analyzed in IMARC's new report titled "Plague Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Plague is a serious and often deadly bacterial infection caused by the bacterium Yersinia pestis. This highly contagious disease is primarily transmitted through fleas that infest rodents, especially rats. The illness can manifest in several forms, with the most common being bubonic, septicemic, and pneumonic. Bubonic plague is characterized by painful swollen lymph nodes (buboes), a high fever, chills, and extreme fatigue. Septicemic plague affects the bloodstream, causing symptoms like abdominal pain, shock, and organ failure. Pneumonic plague, the most virulent form, develops in the lungs and can be transmitted through respiratory droplets, leading to rapid respiratory failure. The diagnosis of this ailment often involves identifying the characteristic symptoms and risk factors, such as exposure to infected rodents or fleas. The healthcare provider may also perform laboratory tests to confirm the presence of Yersinia pestis in bodily fluids or tissue samples. Prompt diagnosis is crucial due to the disease's potential to spread rapidly and cause widespread outbreaks.

The escalating cases of virulent bacterial infections due to inadequate sanitation and poor hygiene practices, which promote the proliferation of rodents and their fleas, are primarily driving the plague market. In addition to this, the inflating utilization of potent therapeutic interventions, such as antibiotics, antimicrobial agents, and supportive care strategies, to effectively manage the affliction and curb its further progression is creating a positive outlook for the market. Moreover, the widespread adoption of public health measures and stringent surveillance protocols, as they play a pivotal role in early detection, isolation, and containment of the disease, is also propelling the market growth. Apart from this, the rising usage of advanced diagnostic techniques, encompassing polymerase chain reaction (PCR) assays, serological tests, and radiological imaging, which aid in the swift and accurate identification of infection in patients, is acting as another significant growth-inducing factor. Additionally, the emerging application of pest control mechanisms, including insecticides and rodent management strategies, to prevent the ailment is also bolstering the market growth. Furthermore, the increasing demand for immune-based therapies, such as monoclonal antibodies and immunomodulatory drugs, that target the virulent bacterium by harnessing the body's immune response to fight against the pathogen is expected to drive the plague market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the plague market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for plague and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the plague market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the plague market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the plague market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current plague marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the plague market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the plague market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the plague market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of plague across the seven major markets?
What is the number of prevalent cases (2018-2034) of plague by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of plague by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with plague across the seven major markets?
What is the size of the plague patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of plague?
What will be the growth rate of patients across the seven major markets?

Plague: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for plague drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the plague market?
What are the key regulatory events related to the plague market?
What is the structure of clinical trial landscape by status related to the plague market?
What is the structure of clinical trial landscape by phase related to the plague market?
What is the structure of clinical trial landscape by route of administration related to the plague market?